Cilostazol ameliorates diabetic nephropathy by inhibiting highglucose- induced apoptosis
10.4196/kjpp.2020.24.5.403
- Author:
Chien-Wen CHIAN
1
;
Yung-Shu LEE
;
Yi-Ju LEE
;
Ya-Hui CHEN
;
Chi-Ping WANG
;
Wen-Chin LEE
;
Huei-Jane LEE
Author Information
1. Division of Nephrology, Department of Paediatrics, Changhua Christian Hospital, Changhua 500, Taiwan
- Publication Type:Original Article
- From:The Korean Journal of Physiology and Pharmacology
2020;24(5):403-412
- CountryRepublic of Korea
- Language:English
-
Abstract:
Diabetic nephropathy (DN) is a hyperglycemia-induced progressivedevelopment of renal insufficiency. Excessive glucose can increase mitochondrialreactive oxygen species (ROS) and induce cell damage, causing mitochondrial dysfunction.Our previous study indicated that cilostazol (CTZ) can reduce ROS levelsand decelerate DN progression in streptozotocin (STZ)-induced type 1 diabetes.This study investigated the potential mechanisms of CTZ in rats with DN and in highglucose-treated mesangial cells. Male Sprague–Dawley rats were fed 5 mg/kg/day ofCTZ after developing STZ-induced diabetes mellitus. Electron microscopy revealedthat CTZ reduced the thickness of the glomerular basement membrane and improvedmitochondrial morphology in mesangial cells of diabetic kidney. CTZ treatmentreduced excessive kidney mitochondrial DNA copy numbers induced by hyperglycemiaand interacted with the intrinsic pathway for regulating cell apoptosis as anantiapoptotic mechanism. In high-glucose-treated mesangial cells, CTZ reduced ROSproduction, altered the apoptotic status, and down-regulated transforming growthfactor beta (TGF-) and nuclear factor kappa light chain enhancer of activated B cells(NF-B). Base on the results of our previous and current studies, CTZ decelerationof hyperglycemia-induced DN is attributable to ROS reduction and thereby maintenanceof the mitochondrial function and reduction in TGF- and NF-B levels.
